PMID

Data

Article Title

Organization

Discovery of novel CDK8 inhibitors using multiple crystal structures in docking-based virtual screening.

West China Hospital of Sichuan University

Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.

West China Hospital of Sichuan University

Rational design and appraisal of selective Cdc2-Like kinase 1 (Clk1) inhibitors as novel autophagy inducers for the treatment of acute liver injury (ALI).

West China Hospital of Sichuan University

Discovery of the GSH responsive "Y-PROTACs" targeting ALK and CDK4/6 as a potential treatment for cancer.

West China Hospital of Sichuan University

Targeting Autophagy-Related Epigenetic Regulators for Cancer Drug Discovery.

West China Hospital of Sichuan University

Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development.

West China Hospital of Sichuan University

Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy.

West China Hospital of Sichuan University

Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer.

West China Hospital of Sichuan University

Discovery of indol-6-yl-pyrrolo[2,3-c]pyridin-7-one derivatives as bromodomain-containing protein 4 (BRD4) inhibitors for the treatment of kidney fibrosis.

West China Hospital of Sichuan University

Synthesis and biological evaluation of a tumor-selective degrader of PARP1.

West China Hospital of Sichuan University

Discovery of 2-Methyl-2-(4-(2-methyl-8-(1

West China Hospital of Sichuan University

Discovery of a Series of Hydroxamic Acid-Based Microtubule Destabilizing Agents with Potent Antitumor Activity.

West China Hospital of Sichuan University

Discovery, Synthesis, and Evaluation of Highly Selective Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) Inhibitor for the Potential Treatment of Metastatic Triple-Negative Breast Cancer.

West China Hospital of Sichuan University

Discovery of 3-(4-(2-((1

West China Hospital of Sichuan University

Discovery of a PROTAC targeting ALK with in vivo activity.

West China Hospital of Sichuan University

-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.

West China Hospital of Sichuan University

Targeting Cysteine Located Outside the Active Site: An Effective Strategy for Covalent ALKi Design.

West China Hospital of Sichuan University

Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers.

West China Hospital of Sichuan University

Pharmacological urate-lowering approaches in chronic kidney disease.

West China Hospital of Sichuan University

Discovery of 4-phenyl-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors.

West China Hospital of Sichuan University

Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms.

West China Hospital of Sichuan University

Design, Synthesis, and Biological Evaluation of Dimorpholine Substituted Thienopyrimidines as Potential Class I PI3K/mTOR Dual Inhibitors.

West China Hospital of Sichuan University